Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03527108
Recruitment Status : Not yet recruiting
First Posted : May 16, 2018
Last Update Posted : August 1, 2018
Bristol-Myers Squibb
Eli Lilly and Company
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : April 1, 2020
  Estimated Study Completion Date : April 1, 2023